🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Bio-Techne Corp DRC (T1CH34)

B3
Currency in BRL
14.50
0.00(0.00%)
Delayed Data
T1CH34 Scorecard
Full Analysis
Trading at a high earnings multiple
Fair Value
Day's Range
13.7014.50
52 wk Range
5.0015.42
Key Statistics
Edit
Bid/Ask
5.00 / 14.28
Prev. Close
14.5
Open
13.7
Day's Range
13.7-14.5
52 wk Range
5-15.42
Volume
0
Average Volume (3m)
191
1-Year Change
51.08%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
T1CH34 Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Cash flows can sufficiently cover interest payments
Show more

Bio-Techne Corp DRC Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Employees
3100
Market
Brazil

Compare T1CH34 to Peers and Sector

Metrics to compare
T1CH34
Peers
Sector
Relationship
P/E Ratio
78.5x−6.6x−0.7x
PEG Ratio
−2.09−0.270.00
Price/Book
5.5x2.2x2.6x
Price / LTM Sales
10.1x3.8x3.2x
Upside (Analyst Target)
-29.8%45.2%
Fair Value Upside
Unlock8.6%7.0%Unlock

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 0.955
Dividend Yield
0.29%
Industry Median 0.01%
Annualised payout
0.0417
Paid quarterly
5-Years Growth
-
Growth Streak

FAQ

What Is the BioTechne (T1CH34) Stock Price Today?

The BioTechne stock price today is 14.50

What Stock Exchange Does BioTechne Trade On?

BioTechne is listed and trades on the B3 stock exchange.

What Is the Stock Symbol for BioTechne?

The stock symbol for BioTechne is "T1CH34."

Does BioTechne Pay Dividends? What’s The Current Dividend Yield?

The dividend yield is 0.29%.

What Is the BioTechne Market Cap?

As of today, BioTechne market cap is 69.21B.

What is BioTechne Earnings Per Share?

The BioTechne EPS is 0.955.

From a Technical Analysis Perspective, Is T1CH34 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.